Acquisition of Entocort Rights and Strengthening of the Inflammatory Bowel Disease Business
First written in FY2016. 10 of 29 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1Revenue DeclineAnnual report
「Entocort 1,850,690 - 1,850,690 - 1,850,690」
According to the revenue breakdown, Entocort sales declined from ¥2,630.933 million in the first half of the previous fiscal year to ¥1,850.690 million. - FY2025Sales growth led by CanadaAnnual report
「Sales of the inflammatory bowel disease treatment Entocort (Japanese brand name: Zentacort) increased, supported by strong sales in Canada and the impact of foreign exchange rates.」
While struggles due to generic competition in some overseas countries had been reported through the previous period, sales increased in the current fiscal year, supported by strong performance in Canada. - FY2024-Q2RestatedAnnual report
「Meanwhile, the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) struggled due to the impact of generic drugs being launched in some overseas countries.」
Struggles caused by generic launches in some overseas regions have continued. - FY2024-Q1Overseas struggles due to generic competitionAnnual report
「Meanwhile, the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) struggled due to the impact of generic drugs being launched in some overseas countries.」
The company explained that generics were launched in some overseas countries, causing Entocort/Zentacort to struggle. - FY2023AdvancedAnnual report
「Sales of the inflammatory bowel disease treatment Entocort (Japanese brand name: Zentacort) increased in Canada and Italy, where a local subsidiary was established in 2021 and the company shifted to a direct-sales structure. Although generic drugs were launched in some European countries from September 2022, their impact on performance for the fiscal year was limited.」
Sales of Entocort/Zentacort increased in Canada and Italy, where the company shifted to a direct-sales structure. Although generics were launched in some parts of Europe, their impact on performance for the fiscal year was considered limited. - FY2023-Q3Limited impact from generic launchesAnnual report
「Although generic drugs were launched in some European countries last September, their impact remains limited.」
The company explained that generic drugs had been launched in some European countries for Entocort, but that the impact was limited as of the current date. - FY2023-Q2AdvancedAnnual report
「Sales of the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) also grew in overseas markets, including Canada, the Nordic countries and Italy, where a local subsidiary was established last year, resulting in higher sales.」
Entocort/Zentacort grew in Canada and the Nordic countries, as well as in Italy, where a local subsidiary was established, broadening the regions contributing to overseas sales growth. - FY2023-Q1AdvancedAnnual report
「Sales of the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) were broadly unchanged from the previous year in Japan, while sales increased in overseas markets, including Canada and the Nordic countries, resulting in a substantial overall increase in sales.」
Entocort/Zentacort was broadly unchanged from the previous year in Japan, while sales grew overseas, including in Canada and the Nordic countries, resulting in an overall increase in sales. - FY2022-Q3Sales declined in some regionsAnnual report
「Sales of the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) declined after struggling in some regions, including Canada and Spain.」
Entocort/Zentacort had been recovering and expanding sales through the previous quarter, but struggled in some regions, including Canada and Spain, resulting in a decline in sales. - FY2022-Q2AdvancedAnnual report
「Sales of the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) expanded after nearly overcoming the decline in sales caused by shipment delays during the spread of COVID-19 infections in the previous fiscal year.」
The decline in sales caused by shipment delays during the spread of COVID-19 infections in the previous period was largely overcome, and sales returned to growth. - FY2022-Q1Broadly unchanged year on year due to the impact of price revisionsAnnual report
「Sales of the inflammatory bowel disease treatment Entocort (Japanese brand name: Zentacort) were affected by price revisions in Japan and overseas, but were broadly unchanged overall from the previous year.」
The company explained that, after struggling through the previous period due to inventory adjustments and shipment delays, overall sales were broadly unchanged from the previous year despite the impact of price revisions in Japan and overseas. - FY2021-Q3Improved performance in overseas marketsAnnual report
「Meanwhile, the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) performed steadily, mainly in overseas markets.」
While the product had struggled through the previous period due to overseas inventory adjustments and shipment delays caused by COVID-19, the company explained that performance was steady mainly in overseas markets. - FY2021-Q2Struggles due to shipment delays caused by COVID-19Annual report
「Meanwhile, although the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) performed steadily in some countries, it struggled overall due in part to shipment delays caused by the spread of COVID-19 infections.」
Although performance was steady in some countries, shipment delays caused by the spread of COVID-19 infections added to the difficulties, and Entocort/Zentacort struggled overall, the company explained. - FY2021-Q1Improved performance in some overseas regionsAnnual report
「Meanwhile, the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) performed steadily, mainly in Germany and the Nordic countries.」
While struggles caused by inventory adjustments in some overseas regions had been reported through the previous period, the company explained that performance was steady in the current quarter, mainly in Germany and the Nordic countries. - FY2020-Q3RestatedAnnual report
「Meanwhile, the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) struggled due to the impact of inventory adjustments in some overseas regions.」
Entocort/Zentacort has struggled due to inventory adjustments in some overseas regions, and the situation has continued from the previous quarter. - FY2020-Q2RestatedAnnual report
「Meanwhile, the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) struggled due to the impact of inventory adjustments in some overseas regions.」
Entocort/Zentacort has struggled due to inventory adjustments in some overseas regions, with the same situation continuing from the previous quarter. - FY2020-Q1Struggles due to overseas inventory adjustmentsAnnual report
「Meanwhile, the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) struggled because inventory adjustments became necessary in some overseas regions.」
Entocort/Zentacort required inventory adjustments in some overseas regions, shifting from its previous sales growth trend to struggling performance. - FY2019AdvancedAnnual report
「Meanwhile, sales of the inflammatory bowel disease treatment Entocort (Japanese brand name: Zentacort) expanded steadily, mainly in Japan, Canada, the Nordic countries and Germany.」
The company explained that sales of Entocort/Zentacort expanded steadily in Japan and overseas, adding Germany to the regions previously mentioned. - FY2019-Q3RestatedAnnual report
「Sales of the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) expanded mainly in Japan, Canada and the Nordic countries.」
Sales of Entocort/Zentacort continued to expand, with Japan, Canada and the Nordic countries identified as the main growth regions. - FY2019-Q2RestatedAnnual report
「Meanwhile, sales of the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) expanded mainly in Japan, Canada and the Nordic countries.」
Sales of Entocort/Zentacort continued to expand, with Japan, Canada and the Nordic countries identified as the main growth regions. - FY2019-Q1AdvancedAnnual report
「Meanwhile, sales of the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) continued to expand both in Japan and overseas.」
While delays in sales development following the transfer of sales operations had been reported in some overseas regions in the previous period, the company explained that sales expanded both in Japan and overseas in the current quarter. - FY2018Domestic progress alongside overseas delaysAnnual report
「Meanwhile, sales of the inflammatory bowel disease treatment Entocort (Japanese brand name: Zentacort) expanded steadily in Japan, partly because restrictions on the prescription period were lifted in December 2017, making long-term prescriptions possible. However, sales development lagged behind plan in some overseas regions following the transfer of sales operations from AstraZeneca, and overall revenue increased only slightly.」
Sales expanded in Japan following the start of long-term prescriptions, while sales development lagged in some overseas regions following the transfer of sales operations, resulting in only a slight increase in overall revenue. - FY2018-Q3AdvancedAnnual report
「Meanwhile, sales of the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) increased steadily both in Japan and overseas. In Japan, following the availability of long-term prescriptions from December 2017, we are placing even greater emphasis on market penetration.」
Sales increased in Japan and overseas, and efforts to strengthen market penetration in Japan have been stepped up following the availability of long-term prescriptions from December 2017. - FY2018-Q2Delay in sales development following the transfer of sales operationsAnnual report
「Meanwhile, sales development for the inflammatory bowel disease (IBD) treatment Entocort (Japanese brand name: Zentacort) has lagged behind plan in some regions following the transfer of sales operations from AstraZeneca, and we are working to recover the shortfall.」
It was stated that sales development for Entocort had lagged behind plan in some regions following the transfer of sales operations, and efforts to recover the shortfall were reported. - FY2017AdvancedAnnual report
「For Entocort, the succession of manufacturing and marketing approval rights in major countries, including Europe and Canada, was completed by the end of the current consolidated fiscal year, and sales are steadily expanding.」
The succession of manufacturing and marketing approval rights in major countries was completed by the end of the fiscal year, and Entocort progressed to the stage of expanding sales. - FY2017-Q3AdvancedAnnual report
「Meanwhile, Entocort, an inflammatory bowel disease (IBD) treatment for which our wholly owned subsidiary Tillotts Pharma AG acquired rights worldwide except the United States from AstraZeneca, continued to perform steadily. In Japan, sales of the Crohn's disease treatment Zentacort Capsules 3mg began in November last year.」
Entocort continued to perform steadily, and sales of Zentacort began in Japan in November 2016. - FY2017-Q2AdvancedAnnual report
「Entocort, an inflammatory bowel disease (IBD) treatment for which our wholly owned subsidiary Tillotts Pharma AG acquired rights worldwide except the United States from AstraZeneca in July last year, has continued to perform steadily and contributed to sales and profit. In Japan, manufacturing and marketing approval was obtained in September this year for the Crohn's disease treatment Zentacort Capsules 3mg, and preparations for its launch are under way.」
Entocort continued to contribute to sales and profit, while in Japan it obtained manufacturing and marketing approval as Zentacort and progressed to the launch-preparation stage. - FY2017-Q1RestatedAnnual report
「Entocort, an inflammatory bowel disease (IBD) treatment acquired by our wholly owned subsidiary Tillotts Pharma AG from AstraZeneca in July 2015 with rights worldwide except the United States, has performed steadily and is contributing to sales and profit. Its generic name is budesonide.」
It is explained that Entocort continues to perform steadily and contribute to sales and profit. - FY2016First statedAnnual report
「In July 2015, our wholly owned subsidiary Tillotts Pharma AG acquired from AstraZeneca the rights outside the United States to Entocort, a treatment for inflammatory bowel disease manufactured and marketed by AstraZeneca.」
The rights were acquired during the period, and have contributed to sales and profit since the third quarter.